Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial

BACKGROUND: In the Gynecologic Cancer Intergroup International Collaboration on Ovarian Neoplasms 7 (ICON7) trial, bevacizumab improved progression-free survival in patients with ovarian cancer when used in combination with first-line chemotherapy and as a single-drug continuation treatment for 18 c...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Stark, Dan, Nankivell, Matthew, Pujade-Lauraine, Eric, Kristensen, Gunnar, Elit, Lorraine, Stockler, Martin, Hilpert, Felix, Cervantes, Andrés, Brown, Julia, Lanceley, Anne, Velikova, Galina, Sabate, Eduardo, Pfisterer, Jacobus, Carey, Mark S, Beale, Philip, Qian, Wendi, Swart, Ann Marie, Oza, Amit, Perren, Tim
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Lancet Pub. Group 2013
Konular:
Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3596061/
https://ncbi.nlm.nih.gov/pubmed/23333117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(12)70567-3
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller